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Purpose: To report the outcomes of same-day, bilateral intravitreal anti-vascular endothelial 
growth factor (VEGF) therapy for a consecutive series of patients treated for exudative 
age-related macular degeneration (ARMD).
Methods: A consecutive series of 254 eyes of 127 patients received bilateral, same-day 
anti-VEGF injections of either bevacizumab or ranibizumab between January 1, 2007 and 
July 1, 2008 and the outcomes were assessed. Approval was obtained from the Institutional 
Review Board at the University of Miami Miller School of Medicine.
Results: Bilateral, same-day anti-VEGF injections were well tolerated in all patients receiving the 
therapy. Indication for injection was exudative macular degeneration in all patients. The incidence 
of adverse effects was low, with only four events reported, none of which were serious.
Conclusions: In this study, bilateral anti-VEGF injections performed on the same day were 
preferred over staggered injections and were well tolerated by patients. No major systemic or 
ocular adverse events were noted, despite the presence of risk factors in a subset of patients. 
Given that there are serious, albeit rare, complications following anti-VEGF injection, further 
study with a larger number of patients will be necessary to definitively prove the safety of this 
treatment modality.
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Introduction
Vascular endothelial growth factor (VEGF) is increasingly recognized as an important 
etiologic agent in several ophthalmic disease processes. Besides its antineoplastic 
properties, anti-VEGF has been shown to be effective in the treatment of various eye 
conditions such as exudative age-related macular degeneration (ARMD), diabetic 
macular edema, and retinal vein occlusions.1–3 Because of their proven efficacy and 
safety profiles, anti-VEGF agents are increasingly being used to augment or even 
supplant other therapeutic modalities.
Not infrequently, multiple injections are required to treat exudative ARMD. 
A patient with active bilateral disease may require twice-monthly visits to his/her 
treating ophthalmologist for an extended period of time, assuming that the bilateral 
injections are given in a staggered fashion. This frequency of treatment would pose a 
significant burden on patients’ time and productivity, and it increases the administrative 
load on the health care system.
Prior to the advent of anti-VEGF therapy, many intravitreal injections in patients 
with bilateral ocular disease were of triamcinolone. As intravitreal triamcinolone 
(IVTA) is opaque and has a significant incidence of transient visual symptoms that 
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may last for hour or days, bilateral, same-day injections are 
usually contraindicated owing to the possibility that both eyes 
may simultaneously experience vision-limiting media opacity 
immediately following injection. The anti-VEGF agents, 
such as ranibizumab (rhuFab V2; Lucentis®, Genentech, 
South San Francisco, CA, USA) and bevacizumab (Avastin®, 
Genentech, South San Francisco, CA, USA) have proven to 
have an acceptable safety profile with low rates of cataract 
formation, elevated intra-ocular pressure (IOP), endophthal-
mitis, and retinal detachment.4,5 As these medications are 
transparent, transient visual reduction due to media opacity 
is typically less pronounced than with triamcinolone. The 
theoretical risk of functional visual decline from bilateral, 
same-day anti-VEGF injection is therefore quite low. In this 
article, we report on our experience with patients treated with 
bilateral, same-day anti-VEGF therapy.
Methods
Cases consisted of 254 eyes from 127 consecutive patients 
given bilateral, same-day injections of either ranibizumab 
or bevacizumab between January 1, 2007 and July 1, 2008. 
All patients were under the care of a single ophthalmologist 
(TGM) at the Bascom Palmer Eye Institute (Miami, FL, 
USA). One patient was excluded from analysis as she was 
lost to follow up.
Pre-injection clinical features recorded were age, 
  indication for injection, drug injected, concentration 
and volume of injection, and Snellen visual acuity (VA). 
Post-injection visual acuity, adverse events, and need 
for additional injection were also examined. All patients 
  underwent examination with Stratus optical coherence 
tomography (Stratus OCT™) (Carl Zeiss Meditec, Inc.; 
Dublin, CA, USA) immediately prior to injection and at 
each follow-up visit. Pre- and post-injection central retinal 
thicknesses were recorded. Presence or absence of a pigment 
epithelial detachment (PED) was also recorded.
This study was approved by the Institutional Review 
Board of the University Of Miami, Miller School of 
  Medicine. Informed consent was obtained from each patient 
prior to injection. In patients receiving bevacizumab, the 
off-label use of the medication was discussed with the patient 
in detail. All patients studied received either 1.25 mg/0.05 mL 
of bevacizumab or 0.5 mg/0.05 mL of ranibizumab injected 
intravitreally through the pars plana in each eye. Each 
eye was prepared in a sterile manner and injected separately. 
The preparation was the standard pre-injection protocol 
for the Bascom Palmer Eye Institute, which includes 10% 
povidone-iodine to the periorbital skin and lashes followed 
by insertion of a sterile eyelid speculum and alternating 
  instillation of three rounds of 5% povidone-iodine and three 
rounds of a sterile aliquot of 4% lidocaine to the inferior 
fornix and conjunctiva at the injection site. No drops or 
equipment were reused in the preparation of the second eye. 
Post-injection, each patient was placed on a treatment of 
topical fourth-generation fluoroquinolone 4 times per day 
for 4 days.
Results
A total of 1322 injections was performed on 254 eyes from 
127 patients (43 men, 84 women). Mean patient age was 
82.5 years (median = 83, range = 56–101). The length of 
the follow-up period was 1–26 months, with a mean and 
median follow-up period of 14.2 months and 15.3 months, 
respectively. Indication for treatment was bilateral exudative 
ARMD in all patients. Of the patients studied, 32 had never 
had an intravitreal anti-VEGF injection before, 57 had a his-
tory of unilateral anti-VEGF injection, and 38 had a history 
of bilateral anti-VEGF injections given in a staggered fashion 
(3–10 days between injections). One patient was excluded 
from analysis due to lack of follow-up examination data.
Twenty-two patients (17%) were on oral anticoagulation 
therapy with warfarin or clopidogrel at the time of injec-
tion; one patient (1%) was using aspirin/dipyridamole; and 
31 patients (24%) were taking aspirin (one of these patients 
was on both aspirin and warfarin). Eighty-one patients (60%) 
had a history of hypertension; four patients (3%) had had an 
ischemic stroke; 17 patients (13%) had coronary artery dis-
ease, 6 of whom (5%) had had a myocardial infarction. Three 
patients (2%) had a unilateral pigment epithelial detachment 
(PED), and one patient (1%) had bilateral pigment epithelial 
detachments at the time of first bilateral injection.
Mean Snellen VA, pre-injection, was 20/175 in the better 
eye (n = 127) and 20/1175 in the worse eye (n = 127). Mean 
pre-injection central retinal thickness (CRT), as determined 
by OCT, was 238 microns (n = 251). One month after the 
first bilateral injection, mean VA was 20/144 (n = 116) in the 
better eye and 20/1050 (n = 116) in the worse eye; mean CRT 
was 235 (n = 232). Of the 119 patients with at least 3 months 
of follow-up, mean visual acuity at 3 months post-injection 
was 20/127 (n = 119) in the better eye and 20/973 (n = 119) 
in the worse eye (the mean pre-injection visual acuity for this 
subset of patients was 20/175 in the better eye and 20/1020 
in the worse eye). Mean CRT was 248 (n = 138) at 3 months 
after the first injection.
A mean of 5.2 bilateral injections was performed per 
patient. 107 patients (84%) required bilateral reinjection Clinical Ophthalmology 2010:4 705
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during the follow-up period, and 13 patients (10%) 
required subsequent unilateral injection. The mean interval 
to second injection was 1.3 months (median = 1 month, 
range = 3 weeks–5 months). Seven patients required no 
subsequent injections in either eye. Indication for reinjection 
was any residual or new intraretinal and/or subretinal fluid, 
found via OCT analysis.
Adverse events following injection were recorded after 4 
injections. Three patients reported pain and/or tearing follow-
ing injection and 1 patient had an episode of supraventricular 
tachycardia requiring transfer to a local hospital. No eyes 
developed endophthalmitis, anterior chamber cell or flare, 
vitritis, vitreous hemorrhage, retinal detachment, or retinal 
pigment epithelial tear. Eight patients died during the follow-
up period as identified by the Social Security Death Index 
(SSDI). No patients had a myocardial infarction or stroke.
Discussion and conclusions
The safety and efficacy of bevacizumab and ranibizumab have 
been shown in several studies.1–5 Outcomes from bilateral, 
same-day injections of these agents, however, have only 
recently begun to be elucidated. This retrospective study pres-
ents early data showing that bilateral, same-day injections are 
well received by patients and seem to have minimal adverse 
effects in the limited number of patients studied.
Prior to the advent of the anti-VEGF agents, bilateral, 
same-day intravitreal injections were usually performed only 
in patients with sight-threatening disease. There is a long 
history of bilateral injection of intravitreal antibiotics and 
antivirals for conditions such as viral retinitis and endogenous 
endophthalmitis. Efficient study of the safety and tolerability 
of such injections, however, is precluded by a high instance 
of disease-related complications. With bevacizumab and 
ranibizumab, some of the recognized serious adverse events 
following intravitreal injection include retinal pigment 
  epithelial tear, retinal detachment, endophthalmitis, vitreous 
hemorrhage, and a possible increase in stroke risk.1,4,6,7 In our 
study, none of these serious adverse events occurred in any 
patient; however, larger numbers of patients will need to be 
studied to ensure there is no significant increase in the risk 
of these complications.
While an interim analysis of the SAILOR (safety 
  assessment of intravitreal Lucentis for AMD) data have 
  suggested a statistically significant increase in stroke risk 
in patients receiving 0.5 mg of intravitreal ranibizumab 
when compared to those receiving a lower, 0.3 mg, dose, the 
MARINA (minimally classic/occult trial of the anti-VEGF 
antibody ranibizumab in the treatment of neovascular AMD) 
and ANCHOR (Anti-VEGF antibody for the treatment 
of predominantly classic choroidal neovascularization 
(CNV) in AMD) studies revealed no statistically significant 
  difference.1,8 Similar analysis of pharmacokinetic data for 
  rabbits has shown that the serum concentration of ranibizumab 
following intravitreal injection is 1500 fold lower than the 
intravitreal concentration.9 The role of VEGF in stroke is still 
unclear and further prospective study is required to elucidate 
the possible association of anti-VEGF agents with stroke. 
In this study, no ischemic strokes were reported. Given the 
uncertainty of stroke risk with these agents, it may be wise to 
consider staggered therapy in patients with strong risk factors 
for ischemic stroke (history of stroke/ischemia, uncontrolled 
hypertension, etc.).
Given the association of the anti-VEGF agents with retinal 
pigment epithelial (RPE) tear, it is possible that bilateral, 
same-day injections may result in bilateral occurrence of 
such an event. Only one case report of bilateral RPE tear was 
found in our literature search; Norose et al reported a case 
of an RPE tear following argon laser photocoagulation of a 
4 × 6-disc-diameter pigment epithelial detachment (PED) in 
the patient’s right eye followed by a spontaneous RPE tear 
along the margin of a 1-disc-diameter PED in the untreated 
fellow eye 5 days later.10 No bilateral RPE tears have been 
reported with anti-VEGF therapy. However, Chang and Sarraf 
reviewed all published cases of RPE tear after anti-VEGF 
therapy and showed that all RPE tears associated with this 
therapy occurred in the setting of exudative ARMD, specifi-
cally in patients with fibrovascular PED or PED associated 
with choroidal neovascularization.6 Kook et al reported the 
incidence of RPE tear in patients with exudative ARMD and 
PED that had been treated with bevacizumab to be 18%.11 
Given this high incidence, administering bilateral, same-day 
injections may warrant caution in patients with bilateral PED. 
It is worth noting, however, that Chang and Sarraf showed that 
the mean time between anti-VEGF injection and diagnosis of 
RPE tear is 4.5 weeks,6 suggesting that concomitant bilateral 
injections may pose no greater risk than would a staggered 
strategy.
With IVTA, post-injection inflammation can lead to 
decline of visual acuity and can even mimic endophthalmitis 
in some cases.12 Uveitis and vitritis have been reported 
  following injection of anti-VEGF agents, but the incidence of 
this side effect appears to be low.4,13 Kiss et al prospectively 
studied 61 patients that received intravitreal bevacizumab 
with a laser flare meter and showed that no patient had any 
significant anterior segment inflammatory response in the 
  follow-up interval.14 Similarly, Spaide et al examined 266 eyes Clinical Ophthalmology 2010:4 706
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of 266 patients that had received intravitreal bevacizumab 
for CNV secondary to ARMD and found that a mild vitritis 
was present in three patients.13 The vitritis, however, did 
not present until 1 month post-injection in two patients and 
2 months post-injection in the third patient. While an argu-
ment can be made that bilateral, same-day injection may 
lead to bilateral vitritis or pseudoendophthalmitis, the data 
from Spaide et al suggest that the onset may be delayed 
enough that even patients receiving staggered injections 
may have both eyes injected before either eye develops an 
  inflammatory response. Looking at the experience with IVTA, 
Marticorena et al reported a patient presenting with recurrent 
uveitis and vitritis following multiple sessions of IVTA and 
  photodynamic therapy (PDT).15 This report and others suggest 
a potential etiology of hypersensitivity to the drug or vehicle. 
Although post-injection inflammation appears to be lower 
with anti-VEGF agents than with IVTA, clinical experience 
with these agents is limited. It is therefore reasonable to 
  consider a unilateral trial of intravitreal anti-VEGF therapy 
in non-emergent patients with no injection history to establish 
that the drug is well tolerated.
Another concern with injection of any intravitreal agent 
bilaterally is the possibility of simultaneous intraocular 
  hemorrhages in both eyes. While subconjunctival hemorrhage 
is often seen following injection, it is rarely visually 
  significant. Submacular and vitreous hemorrhage, however, 
are of concern given the potential for a large decrease in 
visual function for a prolonged period of time. Chieh et al 
have reported a case of submacular hemorrhage that occurred 
4 weeks after bevacizumab therapy for occult CNV in 
ARMD.16 Similarly, Cleary et al assessed the effects of 
intravitreal injections of bevacizumab in 112 eyes and found 
three instances of submacular hemorrhage.17 Wu et al had 
one episode of vitreous hemorrhage in their study of 4303 
intravitreal bevacizumab injections in 1310 consecutive 
eyes.4 The rates of submacular hemorrhage and vitreous 
hemorrhage appear to be quite low; however, the onset 
of bilateral intraocular hemorrhage has the potential to be 
  visually devastating. As bevacizumab given intravenously for 
cancer treatment has been shown to increase the risk of both 
  bleeding and thrombosis,18 the risk of vitreous hemorrhage 
may be increased in patients receiving intravitreal anti-VEGF. 
Although there are no data on the risk profile of patients 
receiving intravitreal anti-VEGF therapy that are also on 
anticoagulation therapy, it is plausible that such patients 
may be at increased risk for intraocular bleeding events. As 
mentioned above, in our study, 23% of the patients were on 
aspirin and 19% were taking the anticoagulants warfarin, 
clopidogrel, or aspirin/dipyridamole, and no patients 
  experienced any intraocular hemorrhage.
While this study did not formally address the question 
of satisfaction after bilateral injections, it has been our 
  experience that patients with bilateral AMD prefer 
  concomitant, same-day injections over staggered injections. 
In the subset of our patients that had previously undergone 
staggered bilateral injection, many have had multiple sets of 
bilateral, same-day injections and very few have switched 
back to the staggered injections. Further prospective study of 
all patients offered bilateral, same-day injections, involving 
a formal satisfaction questionnaire, would be helpful in 
objectively assessing patient preference.
A transient decline in vision after intravitreal injections 
has not been described in the literature; however, our 
  anecdotal experience has shown a widely variable range of 
visual decline secondary to toxicity from the preparation 
or post-injection media opacity from the agent itself that 
may last for several days. We therefore utilized a treatment 
strategy of staggered injections in patients requiring bilateral 
therapy with IVTA. As bevacizumab and ranibizumab are 
both transparent, media opacity is much less of a concern in 
patients treated with these agents. The index of refraction of 
bevacizumab and ranibizumab is essentially equivalent to that 
of 0.9% normal saline at 1.33, whereas the index of refraction 
of the normal adult vitreous fluid is 1.337. This slight 
  difference may be enough to cause transient visual symptoms 
(floaters, mild distortion) following injection, but is likely 
not great enough to significantly affect visual acuity. An 
interesting avenue of further study would be to assess visual 
acuity immediately after anti-VEGF injection and compare 
it with that following IVTA and sham injection. In addition 
to changes in visual acuity induced by the intravitreal agent, 
there may be a significant effect on vision from the topical 
application of lidocaine or povidone-iodine solutions onto the 
cornea, corneal surface changes from lid speculum-induced 
dry eye, and corneal epithelial alteration resulting from the 
decreased blink response after topical anesthesia. As many 
patients who require anti-VEGF therapy often have visual 
acuity that limits their ability to read, work, or drive legally, 
quantification of the visual effects of sterile preparation and 
injection of various intravitreal agents would be helpful in 
post-injection functional counseling.
In summary, because bevacizumab and ranibizumab are 
both transparent drugs with minimal theoretical risk of transient 
visual decline, concomitant bilateral injections may be used in 
appropriate patients. In our study, we noted no serious adverse 
effects from such a treatment strategy despite the presence Clinical Ophthalmology 2010:4
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of significant risk factors. Care should be taken with patients 
  currently on anticoagulation therapy, with those having 
  bilateral PED, and with patients having significant stroke risk 
factors, as these patients may experience simultaneous onset 
of systemic or bilateral ocular adverse effects that could limit 
their visual acuity. Adopting a staggered injection strategy in 
such patients might reduce the risk of bilateral complications 
that may significantly limit a patient’s ability to function in 
his/her activities of daily living.
Bilateral injections of ranibizumab and bevacizumab are 
well tolerated and in many instances are preferred by patients 
with a prior history of staggered injections. When compared 
to staggered injections, a bilateral, same-day injection 
  strategy is beneficial in that it decreases the administrative 
load on the health care system (eg, fewer appointments, lower 
number of insurance claims to submit and process), reduces 
the amount of time patients spend in the office, and frees up 
appointment slots for other patients.
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